Takis’ Post

Evaxion Biotech Receives Positive Feedback on Patent Application for AI-Based Cancer Vaccine Target Identification Method 🖋️ We are thrilled to announce that Evaxion has received positive feedback on our patent application for an innovative AI-based method to identify novel cancer vaccine targets. The International Preliminary Report on Patentability (IPRP) highlights the novelty and inventiveness of our claims, indicating promising prospects for obtaining granted patents and protecting the invention. This endorsement underlines our commitment to revolutionizing cancer treatment through our AI-Immunology™ platform, which can identify a novel category of tumor vaccine targets derived from Endogenous Retroviruses (ERVs). These ERVs, dormant viral remnants in our genome, are promising targets for our personalized vaccines, expanding treatment possibilities for cancer patients. Our CEO, Christian Kanstrup, emphasized the importance of this feedback: "This validation from the World Intellectual Property Organization supports our innovative approach and strengthens our position in the field." Stay tuned as we continue to advance our AI-driven solutions to meet high unmet medical needs in cancer treatment. #Evaxion #CancerTreatment #ERVs #Innovation #PersonalizedMedicine #Biotech #IPRP

🔬🎓 Exciting Announcement from my PhD Research! 🎓🔬 I'm happy to share my recent publication stemming from my doctoral work. Title: "Unveiling the Mechanisms of Extracellular ATP-Mediated Drug Resistance in Human Cancer Cells: Insights from Temporal and Spatial Dynamics" In our study, we delved into the complex landscape of drug resistance mechanisms in cancer, a critical aspect contributing to a significant number of cancer-related deaths. Our investigation spanned diverse temporal and spatial mechanisms, shedding light on how ATP-binding cassette (ABC) transporters, epithelial-mesenchymal transition (EMT), cancer stem cells (CSCs), glutathione (GSH), senescence, and vacuole-type ATPase (V-ATPase) collectively orchestrate resistance to drug therapies. One of the pivotal findings of our research is the role of extracellular ATP (eATP) in driving drug resistance. We uncovered that eATP not only induces and regulates EMT, CSC formation, and ABC transporters but also consistently upregulates Stanniocalcin-1 (STC1), a gene intricately linked with these processes and tumor growth. Furthermore, our study elucidates a novel pathway through which eATP enhances drug resistance in cancer cells. By mediating eATP internalization via macropinocytosis, intracellular ATP (iATP) levels are elevated, culminating in the induction of EMT and CSC formation, thus fostering drug resistance. This comprehensive investigation represents a significant advancement in our understanding of eATP-induced drug resistance, shedding light on previously unexplored territory. By unraveling these intricate mechanisms, we pave the way for the development of more targeted and effective therapeutic strategies against drug-resistant cancers. I extend my heartfelt gratitude to my advisors, colleagues, and collaborators for their invaluable support and contributions throughout this journey. Together, we're making strides in the fight against cancer. Read the full paper here: https://lnkd.in/eShruD3z and let's continue pushing the boundaries of cancer research together! #PhDResearch #CancerDrugResistance #ExtracellularATP #EMT #CancerStemCells #Innovation

High-throughput screening (HTS) has revolutionized the field of #cancerresearch by enabling the rapid and systematic evaluation of compounds for their potential as anticancer agents. This approach represents a pivotal step in the early stages of cancer #drugdiscovery. Read our new blog, Harnessing Microplate Readers for Cancer Research, to learn more about the pivotal role microplate readers play in identifying potential anticancer agents and advancing the understanding of cancer biology through large-scale, systematic screening efforts. https://lnkd.in/g5mkH2Wd

Excellent reporting from Melanie Senior of Nature Biotechnology on the current radiopharma landscape. Radiopharmaceuticals use radioactive isotopes to deliver powerful radiation directly to cancer cells, minimizing hard to healthy tissue. Here’s why they’re generating so much excitement: 🎯 More precise attacks: Unlike some other targeted therapies, radiopharmaceuticals can target a wider range of cancers, including those with low-expression targets. 🎯 Dual-purpose: They can not only kill cancer cells but also help doctors see where the tumor is located and how well the treatment is working. 🎯 Reduced side effects: Early results suggest radiopharmaceuticals may be gentler on patients than some other treatments. Read the full article: https://lnkd.in/ep_Na-ma

Imagine a future where cancer treatments are perfectly tailored to each patient's unique cellular makeup. NIH researchers are making this a reality with a new AI tool that uses single-cell RNA sequencing to predict drug responses. Discover how this innovation could change the future of oncology. Learn more here: https://lnkd.in/e5766Epu We’d love to hear your thoughts! #medicalresearch #clinicaltrials #medicalstudies #miamiclinicalresearch #cancerresearch #cancertreatment #oncology #biotechnology #biomedicalinnovation

🚀 New Blog Post: Harnessing Microplate Readers for Cancer Research: Blog #1 High-Throughput Drug Screening🔬 Discover how High-Throughput Screening (HTS) is accelerating the fight against cancer in our latest blog. HTS is pivotal in early cancer drug discovery, rapidly evaluating millions of compounds to identify potential anticancer agents. 🧬 Our post delves into the crucial role of microplate readers in HTS, enabling efficient analysis of biological parameters essential in cancer research. These readers, along with advanced robotics, liquid handling technology, and specialized software, are driving forward the discovery of new treatments. 🌐 This synergy of technology is not just enhancing our understanding of cancer biology; it's paving the way for innovative cancer treatments. Read more about how these technologies are shaping the future of cancer research in our latest blog. https://lnkd.in/g5mkH2Wd #CancerResearch #HighThroughputScreening #Innovation #DrugDiscovery

CALL FOR BOOK CHAPTERS Dear Scholars, Researchers, and Practitioners, You are cordially invited to submit your manuscripts for the forthcoming book title: “  "Analyzing Terpenes' Role in Cancer Treatment,"  to be published by IGI Global, an international publisher of progressive academic research. You are invited to submit on or before June 2, 2024, a chapter proposal of 1,000 to 2,000 words clearly explaining the mission and concerns of his or her proposed chapter (including title, authors list, affiliations, abstract, Email ID of the corresponding author, keywords and chapter outline). Authors will be notified by July 3, 2024, about the status of their proposals and sent chapter guidelines.  The proposed book chapters are: 1.      An introduction :Terpenes as anticancer  2.          Terpenes targeting liver cancer 3.          Terpenes on the Frontlines: Potential Benefits in Breast Cancer: 4.          Shielding the skin: Terpenes and skin cancer 5.          Nature's Warriors: Exploring Terpenes for Prostate Cancer Management 6.          Terpenes and Lung cancer 7.          Terpenes in colon cancer battlefield 8.          Terpenes in treatment of ovarian cancer 9.          Gene drug delivery for the treatment cancer 10.        Terpene and Nanotechnology: Target drug delivery 11.        Nutraceuticals and Terpene Integration for the cancer treatment 12.        Synergistic Magic: Combining Terpenes with Other Drugs for Potentiated Effects 13.        Marine world of terpenes: Targetting specific cancer 14.        Clinical and Preclinical Studies on Terpenes efficacy in cancer 15.        Terpene-Based Antitumor Compositions: A patent landscape 16.        Terpenes and Detoxification Support: Enhancing the Body's Natural Defense   Any other topic with reference to the context is also invited. Interested candidates mail me at bhawnachopra2009@gmail.com

Can AI predict cancer drug response at the single-cell level? "Researchers suggest using single-cell RNA sequencing data to more precisely match cancer patients with effective drugs." AI tool analyzes tumors at single-cell level to predict drug responses, a potential breakthrough in personalized cancer treatment.

The Power of Science and AI will allow us to match a cancer patient’s individual cells to tailored drugs for optimal response. Current approaches to matching patients to drugs rely on bulk sequencing of tumor DNA and RNA which takes an average of all the cells in the tumor sample. While this is moving us toward matching patients with the right treatments, we know that tumors contain many types of sub-populations, or clones, that may react differently to specific drugs leading to a lack of response. Alternatively, single-cell RNA sequencing provides much higher resolution data, down to the single-cell level, but it is more costly and not yet widely available in clinical settings.  Faced with this dilemma, researchers have used transfer learning to train AI models to predict drug response using bulk RNA. These AI models accurately predicted how individual cells would respond to both single drugs and combination drugs for 44 FDA-approved cancer drugs. Imagine a day when patients never have to be told that they are not responding to their treatment. That’s the day there is no more fear of cancer. #cancer #innovation https://lnkd.in/gaDhbZpx

When I speak to people in the oncology drug discovery and development industry, one particular problem seem to be top of mind for everyone. The problem of not finding appropriate in vivo models that recapitulates key aspects of tumour biology. I think this is not the only problem. It is only reasonable for labs to start testing drug candidates on more stable and reliable models such as cell lines before testing on more complex models. Without matching cell line-derived xenografts (CDX), scientists would have a strong battle with tumour heterogeneity and this can complicate drug development. By using cell lines derived from patient tumours and subsequently generating CDX models in immunocompromised mice, researchers can better capture the complexity and heterogeneity of human cancers. Crown Bioscience has over 500 validates cancer cell lines available to clients to test their drug responses. 200 of these cell lines have matching CDX to allow clients seamlessly migrate candidates into in vivo tests after in vitro screening and tests. This presents a powerful solution to researchers looking to quickly advance their oncology candidates as this saves enormous time, money and life in the long run. #oncology #cancerresearch #drugdevelopment #innovation https://lnkd.in/d3YqA2Wm).